You can buy or sell RDHL and other stocks, options, ETFs, and crypto commission-free!
Redhill Biopharma Ltd. American Depositary Shares, also called Redhill Biopharma, is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. Read More It operates through two segments: Commercial Operations and Research & Development. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's U.S. subsidiary. The Research and Development segment includes all activities related to the research and development of therapeutic candidates and is being performed by the Company. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
Tel Aviv, Tel Aviv
52 Week High
52 Week Low
Research And Development
Seeking AlphaFeb 26
RedHill Biopharma's (RDHL) CEO Dror Ben-Asher on Q4 2018 Results - Earnings Call Transcript
RedHill Biopharma Ltd. (NASDAQ:RDHL) Q4 2018 Earnings Conference Call February 26, 2019 8:30 AM ET Company Participants Dror Ben-Asher – Chief Executive Officer Micha Ben Chorin – Chief Financial Officer Gilead Raday – Chief Operating Officer Conference Call Participants Allen Cha – Nomura Scott Henry – Roth Capital Steve Brozak – WBB Securities Matt Kaplan – Ladenburg Swayampakula Ramakanth – H.C.Wainwright Robin Garner – LifeSci Capital Jonas Peciulis – Edison Ed Woo – Ascendiant Capital Ope...
Associated PressFeb 26
RedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today reported its full-year 2018 financial results and operational highlights. Key Highlights: -- Positive top-line results from the confirmatory Phase 3 study with TALICIA® for eradication of H. pylori infection; NDA filing expected in H1/19 with ...
Associated PressFeb 19
RedHill Biopharma to Present at the 8th Annual SVB Leerink Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the 8th Annual SVB Leerink Healthcare Conference on Friday, March 1, 2019, at 9:30 a.m. EST, at the Lotte New York ...
Expected May 28, Pre-Market